Anti-VEGF Monoclonal Antibody
Phase 2
Anti-VEGF Monoclonal Antibody is one of 3 therapeutic programs targeting Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
#DrugCompanyPhaseTrials
1Avastin
RochePhase 2
TRODELVY
GileadPhase 2
Anti-VEGF Monoclonal Antibody
NNational Cancer Institute (NCI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)